Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + selumetinib
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of capecitabine, a fluoropyrimidine carbamate prodrug that converts to 5-fluorouracil (5-FU) in tumor cells, and selumetinib, a selective MEK 1/2 inhibitor that targets the MAPK signaling pathway. This combination has been studied in clinical trials for advanced pancreatic cancer.
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + selumetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + selumetinib.